TY - JOUR
T1 - Acceleration of tendon healing using US guided intratendinousinjection of bevacizumab
T2 - First pre-clinical study on a murine model
AU - Dallaudière, Benjamin
AU - Lempicki, Marta
AU - Pesquer, Lionel
AU - Louedec, Liliane
AU - Preux, Pierre Marie
AU - Meyer, Philippe
AU - Hess, Agathe
AU - Moreau Durieux, Marie Hèlène
AU - Hummel, Vincent
AU - Larbi, Ahmed
AU - Deschamps, Lydia
AU - Benayoun, Yohan
AU - Journe, Clement
AU - Perozziello, Anne
AU - Schouman-Claeys, Elisabeth
AU - Michel, Jean Baptiste
AU - Serfaty, Jean Michel
PY - 2013/12
Y1 - 2013/12
N2 - Purpose: Tendinopathy shows early disorganized collagen fibers with neo-angiogenesis on histology.Peri-tendinous injection of corticosteroid is the commonly accepted strategy despite the abscence ofinflammation in tendinosis. The aim of our study was to assess the potential of intratendinous injectionof an anti-angiogenic drug (bevacizumab, AA) to treat tendinopathy in a murine model of patellar andAchilles tendinopathy, and to evaluate its local toxicity.Materials and method: Forty rats (160 patellar and Achilles tendons) were used for this study. We inducedtendinosis (T+) in 80 tendons by injecting under ultrasonography (US) guidance Collagenase 1(day0 = D0, patellar = 40 and Achilles = 40). Clinical examination and tendon US were performed at D3, imme-diately followed by either AA (AAT+, n = 40) or physiological serum (PST+, n = 40, control) US-guidedintratendinous injection. Follow-up at D6 and D13 using clinical, US and histology, and comparisonbetween the 2 groups were performed. To study AA toxicity we compared the 80 remaining normaltendons (T?) after injecting AA in 40 (AAT?).Results: All AAT+ showed a better joint mobilization compared to PST+ at D6 (p = 0.004) with thinner UStendon diameters (p <0.004), and less disorganized collagen fibers and neovessels on histology (p <0.05).There was no difference at D13 regarding clinical status, US tendon diameter and histology (p > 0.05).Comparison between AAT? and T? showed no AA toxicity on tendon (p = 0.18).Conclusion: Our study suggests that high dose mono-injection of AA in tendinosis, early after the beginningof the disease, accelerates tendon's healing, with no local toxicity.
AB - Purpose: Tendinopathy shows early disorganized collagen fibers with neo-angiogenesis on histology.Peri-tendinous injection of corticosteroid is the commonly accepted strategy despite the abscence ofinflammation in tendinosis. The aim of our study was to assess the potential of intratendinous injectionof an anti-angiogenic drug (bevacizumab, AA) to treat tendinopathy in a murine model of patellar andAchilles tendinopathy, and to evaluate its local toxicity.Materials and method: Forty rats (160 patellar and Achilles tendons) were used for this study. We inducedtendinosis (T+) in 80 tendons by injecting under ultrasonography (US) guidance Collagenase 1(day0 = D0, patellar = 40 and Achilles = 40). Clinical examination and tendon US were performed at D3, imme-diately followed by either AA (AAT+, n = 40) or physiological serum (PST+, n = 40, control) US-guidedintratendinous injection. Follow-up at D6 and D13 using clinical, US and histology, and comparisonbetween the 2 groups were performed. To study AA toxicity we compared the 80 remaining normaltendons (T?) after injecting AA in 40 (AAT?).Results: All AAT+ showed a better joint mobilization compared to PST+ at D6 (p = 0.004) with thinner UStendon diameters (p <0.004), and less disorganized collagen fibers and neovessels on histology (p <0.05).There was no difference at D13 regarding clinical status, US tendon diameter and histology (p > 0.05).Comparison between AAT? and T? showed no AA toxicity on tendon (p = 0.18).Conclusion: Our study suggests that high dose mono-injection of AA in tendinosis, early after the beginningof the disease, accelerates tendon's healing, with no local toxicity.
KW - Anti-angiogenic
KW - Rat
KW - Tendinosis
KW - Tendon
KW - US
UR - http://www.scopus.com/inward/record.url?scp=84890787674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890787674&partnerID=8YFLogxK
U2 - 10.1016/j.ejrad.2013.06.012
DO - 10.1016/j.ejrad.2013.06.012
M3 - Article
C2 - 24035455
AN - SCOPUS:84890787674
SN - 0720-048X
VL - 82
JO - Journal of Medical Imaging
JF - Journal of Medical Imaging
IS - 12
ER -